このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性卵巣癌の成人女性における REGN5668 のセミプリマブまたは REGN4018 との併用投与に関する研究

2026年9月20日 更新者:Regeneron Pharmaceuticals

セミプリマブまたは REGN4018 (MUC16xCD3) と組み合わせて投与される REGN5668 (MUC16xCD28、共刺激性二重特異性) の第 1/2 相試験

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

調査の概要

研究の種類

介入

入学 (推定)

612

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • 募集
        • City of Hope Comprehensive Cancer Center
      • Irvine、California、アメリカ、92618
        • 募集
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange、California、アメリカ、92868
        • 募集
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa、Florida、アメリカ、33612
        • 完了
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago、Illinois、アメリカ、60637
        • 募集
        • University of Chicago Medical Center
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • 募集
        • Massachusetts General Hospital
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • 募集
        • Karmanos Cancer Institute
    • New York
      • New York、New York、アメリカ、10065
        • 募集
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle、Washington、アメリカ、98109
        • 募集
        • Seattle Cancer Care Alliance at South Lake Union - G3630
      • Girona、スペイン、17007
        • 募集
        • Institut Catala dOncologia Girona
      • Madrid、スペイン、28040
        • 募集
        • Hospital Universitario Fundacion Jimenez
      • Madrid、スペイン、28040
        • 募集
        • Ciudad Universitaria
      • Madrid、スペイン、28041
        • 募集
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela、A Coruna、スペイン、15706
        • 募集
        • Hospital Clinico Universitario Santiago de Compostela
      • Villejuif、フランス、94805
        • 募集
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite、Auvergne-Rhône、フランス、69310
        • 募集
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon、Bourgogne-Franche-Comté、フランス、21000
        • 募集
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux、New Aquitaine、フランス、33076
        • 募集
        • Institut Bergonie
    • Normandy
      • Caen、Normandy、フランス、14076
        • 募集
        • Centre Francois Baclesse (CFB)
      • São Paulo、ブラジル、01509-010
        • 募集
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、ブラジル、90619-900
        • 募集
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos、São Paulo、ブラジル、14784-400
        • 募集
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba、São Paulo、ブラジル、18065-100
        • 募集
        • Unimed Sorocaba
    • Vlaams-Brabant
      • Leuven、Vlaams-Brabant、ベルギー、3000
        • 募集
        • Universitair Ziekenhuis Leuven

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

他の名前:
  • ubletamig

Administer per the protocol

他の名前:
  • REGN2810
  • リブタヨ®

Administer per the protocol

実験的:Module 2

REGN5668 and ubamatamab

Administer per the protocol

他の名前:
  • ubletamig

Administer per the protocol

他の名前:
  • REGN4018

Administer per the protocol

他の名前:
  • ケブザラ®

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Dose Limiting Toxicities (DLT)
時間枠:42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
時間枠:21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
時間枠:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
時間枠:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
時間枠:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
時間枠:Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
時間枠:Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
時間枠:Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
ORR based on RECIST 1.1
時間枠:Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
時間枠:Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年12月8日

一次修了 (推定)

2028年11月8日

研究の完了 (推定)

2028年11月8日

試験登録日

最初に提出

2020年10月9日

QC基準を満たした最初の提出物

2020年10月9日

最初の投稿 (実際)

2020年10月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月20日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 共有時間枠

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共有アクセス基準

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する